Warneford Hospital, University of Oxford
Oxford, Oxfordshire, OX37JX, United Kingdom
Location status: Recruiting
Location contact
Andrea Reinecke, PhD
CONTACT
Andrea Reinecke, PhD
PRINCIPAL_INVESTIGATOR
Rowan Haslam, MSc
CONTACT
NCT Number: NCT07017023
This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Early Phase 1
Oxford, Oxfordshire, OX37JX, United Kingdom
Location status: Recruiting
Andrea Reinecke, PhD
CONTACT
Andrea Reinecke, PhD
PRINCIPAL_INVESTIGATOR
Rowan Haslam, MSc
CONTACT
Behavioural Activation (BA) is a first-line treatment for depression that aims to re-engage patients with rewarding activities, to improve mood. However, patients with low levels of positive mood respond less well to BA than others. Neuroscience has identified deficits in the processing of positive stimuli in this group of people, using cognitive-psychological computer tasks and brain imaging. Losartan, a licensed medication targeting the renin-angiotensin system, has recently been found to improve the processing of positive stimuli in healthy volunteers. Combining losartan with BA may improve treatment response in people with low positive mood, by improving positive information processing. This study will test this hypothesis.
In a double-blind randomised trial, 76 participants with low positive mood will receive 7-day behavioural activation (BA) with daily losartan (50mg) or placebo. Before and after the intervention, they will complete computer tasks measuring processing of positive and negative information.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA
7-day placebo (oral; microcellulose in identical capsules) with 7-day BA
Time frame: from baseline to post 7-day intervention
reinforcement learning, calculated as the learning rate from negative and positive decision outcomes. Larger scores indicate better learning from an outcome.
Time frame: from baseline to post 7-day intervention
mean reaction time of the pull trials of a valence category subtracted from the push trials of the same category, yielding a single indicator of approach/avoidance, with positive scores indicating relatively stronger approach and negative scores indicating relatively stronger avoidance
Time frame: from baseline to post 7-day intervention
% approach vs avoid decisions
Time frame: from baseline to post 7-day intervention
The task weighs effort costs against reward value. It involves a hand dynamometer to record effort. On each trial, participants receive an offer showing a reward (number of apples shown on a tree) and an effort level (height of marking on the tree trunk), which they can accept or reject (Yes/No response). On a subset of accepted trials, participants have to exert physical effort on the hand dynamometer to earn the reward (number of apples in the respective trial). Participants receive monetary reward for the number of apples collected. Key outcome marker is effort-reward valuation, i.e. % accepted trials based on combinations of effort and reward levels. Other outcomes: Force exerted relative to Maximum Voluntary Contraction (MVC), Reaction times of Yes/No.
Contact information is provided by the study sponsor or research team.
Andrea Reinecke, PhD
CONTACT
Rowan Haslam, MSc
CONTACT
University of Oxford
Other
Cognitive Effects of Losartan-augmented Behavioural Activation in Anhedonia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07267559
Cognitive Functioning, Emotional Processing
Oxford, United Kingdom
View Trial DetailsNCT06636812
Anxiety Disorders, Emotional Processing
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT06412315
Behavior, Behavioral Symptoms
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT06628154
Anxiety Disorders, Behavior
Oxford, Oxfordshire, United Kingdom
View Trial Details